BLRX (Nasdaq: BioLineRx): la Bio che tiene a cuore la schizofrenia

alumnum

Nuovo Utente
Registrato
24/8/12
Messaggi
337
Punti reazioni
10
quotata a 3$ ha appena ricevuto un BUY con tp 11$ ....e con esso sono arrivati i volumi....:cool:
 

alumnum

Nuovo Utente
Registrato
24/8/12
Messaggi
337
Punti reazioni
10
La cugina di Rosetta (entrambe made in Israel)....

z

BioLineRx Ltd., a clinical stage biopharmaceutical development company, together with its subsidiaries, engages in identifying, in-licensing, and developing therapeutic candidates. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers; and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The company also has 11 pre-clinical stage development products for various indications, including central nervous system diseases, oncology, infectious diseases, and cardiovascular and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate and develop pre-clinical therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience to develop and commercialize BL-8020 for the treatment of Hepatitis; with Cypress Bioscience, Inc. to develop and commercialize BL-1020 in the United States, Canada, and Mexico; and with Ikaria, Inc. to develop, manufacture, and commercialize BL-1040. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
 

alumnum

Nuovo Utente
Registrato
24/8/12
Messaggi
337
Punti reazioni
10
WATCHLIST! Molta carne al fuoco....

Più mi documento e più realizzo che questo titolo ha molta carne al fuoco....a prima analisi sembra parecchio sottovalutato.....qualcuno che ha voglia di aiutarmi nell'analisi anche grafica?:bow:
 

alumnum

Nuovo Utente
Registrato
24/8/12
Messaggi
337
Punti reazioni
10
24 settembre 2012

Ad esempio:

NEW YORK (MarketWatch) -- Shares of BioLine RX Ltd. (US:blrx) jumped 16% in premarket trades on Monday after the company said it won a notice of allowance from the U.S. Patent and Trademark Office for its BL-1020 drug to treat schizophrenia. When granted, the patent will be valid at least until 2031, which is nine years longer than the granted patent coverage previously reported by the company.
 

alumnum

Nuovo Utente
Registrato
24/8/12
Messaggi
337
Punti reazioni
10
Aegis Analysts Begin Coverage on BioLineRx (BLRX) October 2nd, 2012

BioLineRx, Ltd. (BLRX) -NasdaqCM
3.13 0.52(19.92%) 11:19AM EDT - Nasdaq Real Time Price
52wk Range: 2.20 - 6.87


Analysts at Aegis started coverage on shares of BioLineRx (NASDAQ: BLRX) in a research report issued to clients and investors on Tuesday. The firm set a “buy” rating and a $11.00 price target on the stock.

Shares of BioLineRx traded up 2.35% during mid-day trading on Tuesday, hitting $2.61. BioLineRx has a one year low of $2.20 and a one year high of $6.87. The company’s market cap is $45.9 million.

BioLineRX Ltd. is an Israel-based company engaged in identifying and following the critical pathway to commercialization of therapeutic compounds.

Aegis Analysts Begin Coverage on BioLineRx (BLRX) | Daily Political
 

Gualt

Nuovo Utente
Registrato
4/2/02
Messaggi
549
Punti reazioni
20
buoni volumi in apertura....
 

laniero

Nuovo Utente
Registrato
25/4/06
Messaggi
926
Punti reazioni
24
BioLine Rx Ltd announced results from the Phase IIb EAGLE trial for BL-1020, that BL-1020 demonstrated a increase in efficacy at improving cognitive impairment associated with this condition, as compared to the original analysis of the study. The findings pertain to the results of the Phase IIb EAGLE study, first published in September 2009, for determining safety, efficacy, and tolerability of BL-1020 compared to Risperidone, an approved atypical antipsychotic drug, and placebo. Results of the study showed that BL-1020 was significantly better than the placebo and comparable with Risperidone in both PANSS and CGI scores, which are widely recognized measures of severity and improvement in schizophrenia. In addition, the results showed a statistically significant improvement in cognitive function as assessed by BACS (Brief Assessment of Cognition in Schizophrenia), when compared to both placebo and Risperidone. Results of the re-analysis clearly show that when the time of day for administration of the neurocognitive BACS test was consistent between visits, the beneficial effect of BL-1020 on cognitive function was even more pronounced than the original analysis. Specifically, the original analysis for all patients in the study showed an effect size of 0.40 for BL-1020 versus placebo and an effect size of 0.39 for BL-1020 versus Risperidone